Hyperfine, Inc. Form 8-K Summary
Business context and reporting period
Hyperfine, Inc. filed this Current Report on Form 8-K on September 26, 2022, under Items 5.02 and 5.07. The filing concerns a one-time stock option repricing intended to retain and motivate employees and other key contributors. It does not report quarterly or annual operating results.
Financial and capitalization information
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
- The repricing covers options to purchase up to 5,496,799 shares of Class A common stock, including vested and unvested options.
- The repricing is based on the closing price of the Class A common stock on Nasdaq on the effective date and cannot increase any option’s existing exercise price.
- Management does not expect the repricing to have a material impact on the statement of operations.
Material changes and transaction terms
- Stockholders controlled by Jonathan M. Rothberg, representing a majority of the voting power of the Class A and Class B common stock, approved the repricing by written consent on September 26, 2022.
- The approving stockholders held 1,026,032 Class A shares and 15,055,288 Class B shares, collectively representing 84.7% of voting power.
- The Board approved the repricing on August 24, 2022, subject to stockholder approval.
- Dr. Rothberg’s stock options are excluded. Most non-employee director options are also excluded, except for certain options held by Executive Chairperson and Interim CEO R. Scott Huennekens and director Ruth Fattori.
- The effective date is the 20th calendar day after completion of mailing the definitive Schedule 14C information statement and was expected to be October 31, 2022.
Executive and key-person option information
| Holder | Shares underlying relevant options | Weighted-average exercise price |
|---|---|---|
| R. Scott Huennekens, Executive Chairperson and Interim President and CEO | 1,424,623 | $3.28 |
| Alok Gupta, Chief Financial Officer | 254,333 | $3.90 |
| Khan Siddiqui, Chief Medical Officer and Chief Strategy Officer | 474,978 | $3.76 |
| Neela Paykel, General Counsel, Chief Compliance Officer and Corporate Secretary | 255,000 | $3.66 |
| Dave Scott, Former President and CEO | None disclosed | None disclosed |
Outlook, risks, and unusual items
The principal unusual item is the repricing of eligible employee and selected insider stock options. The filing states that the repricing is not expected to materially affect operations. Forward-looking statements regarding the repricing are subject to risks and uncertainties described in the company’s Form 10-K for the year ended December 31, 2021, and subsequent Form 10-Q filings. The company has no obligation to update these statements.
Investor verification items
- Verify the final effective date and the closing share price used for the repriced options.
- Review the definitive Schedule 14C information statement for the complete list of eligible options, holders, vesting terms, and amended exercise prices.
- Assess the potential dilution from the 5,496,799 shares subject to repricing.
- Review subsequent filings to confirm the accounting expense and any effect on the company’s financial statements.
- Review the latest Form 10-K and Form 10-Q filings for liquidity, operating performance, and risks not addressed in this event filing.